BC Week In Review | Aug 11, 2008
Company News

Meda, Valeant Pharmaceuticals International deal

Meda will acquire Valeant’s Eastern and Western European business operations for $392 million in cash. Meda said the deal gives it a foothold in Russia, where it plans to introduce its own products, as well...
BC Extra | Aug 5, 2008
Company News

Meda acquiring Valeant units in Europe

Valeant (NYSE:VRX) will sell its operations in Western and Eastern Europe, including Russia, to Meda (SSE:MEDA) for $392 million in cash. Meda said the deal gives it a foothold in Russia, where it plans to...
BioCentury | Feb 14, 2005
Strategy

Exit arbitrage

With everybody and their little brother looking to in-license late-stage or marketed products, there aren't enough drugs in the universe to support all the specialty pharma startups of the last few years. Xcel Pharmaceuticals Inc....
Items per page:
1 - 3 of 3